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sive). Non parametric ANOVA analysis was performed to
compare the difference of UCLA-PCI scores by Gleason groups.
RESULTS: A total of 1452 patients were included (mean age:
74.4; SD 8.7). The mean of missing items per patient (0.36)
showed acceptable feasibility. Ceiling effects (£67%) was present
in all dimensions, as well as ﬂoor effects (£48%) in 5 of the 6
dimensions. Cronbach alpha values by dimensions were as
follows: 0.85 for Urinary Function (UF); 0.60 for Bowel Func-
tion (BF); and 0.94 for Sexual Function (SF). For the function
and bother (F-B) related items, internal consistency was: a = 0.51
for Urinary F-B; a = 0.71 for Bowel F-B; and a = 0.89 for Sexual
F-B. There were statistically signiﬁcant between-group differ-
ences in scores on the UCLA-PCI, with patients in Gleason group
A reporting higher scores (better QoL) than Gleason group C.
Likewise, mean differences (MD) in UF dimension scores were
statistically signiﬁcant when comparing Group A to C (MD 
= 6.3, p < 0.001), and Group B to C (MD = 6.4, p < 0.001). In
the BF dimension, MD was signiﬁcant when comparing Group
A to C (MD = 3.9 p = 0.001), and Group B to C (MD = 4.4, 
p = 0.001); and in the SF dimension when comparing Group A
to B (MD = 4.5, p = 0.015), and Group A to C (MD = 7.5, 
p < 0.001). CONCLUSIONS: The Spanish version of the UCLA-
PCI in general showed acceptable psychometric properties,
though further investigation of the substantial ceiling and ﬂoor
effects are required.
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Erlotinib (TarcevaTM) is an oral highly speciﬁc epidermal growth
factor receptor tyrosine kinase inhibitor. Phase II/III clinical trials
have shown clinical efﬁcacy of erlotinib in advanced (stage III/IV)
Non-Small-Cell Lung Cancer (NSCLC) in terms of survival and
increased Health Related Quality-of-Life (HRQoL). There is
limited information of HRQoL and resources utilization on
Canadian population of NSCLC. OBJECTIVE: To determine the
HRQoL and resource utilization components in Canadian
patients with stage III/IV NSCLC. METHODS: A face-to-face
survey was conducted on a cohort of 32 patients with stage III/IV
NSCLC from the lung cancer clinic at Princess Margaret Hospi-
tal, Toronto. HRQoL was assessed using disease speciﬁc tools
(FACT-L). Utility scores were assessed by EQ-5D US English
version. Socio-economic, clinical, and resource utilization data
were collected using a self-administered questionnaire. Partici-
pants’ clinic charts were reviewed for supportive data and veri-
ﬁcation. RESULTS: Mean age was 63.03 ± 10.39 years, 23 were
females and 68.8% have been smokers. Mean time since cancer
diagnosis was 24.06 ± 17.74 months, 78.1% had metastasis. The
average FACT-L score was 99.64 (range: 90–130), the FACT-
L/TOI score was 57.43. The average EQ-5D score was 0.533,
the score for Current Health State was 59.38 (0–10 scale). Mean
number of visits to oncology clinic was 1.06 ± 0.74/month, and
0.86 ± 0.84/month for family physicians. Patients have been hos-
pitalized for 4.13 ± 4.26 days on average in previous year. The
average cost of medical imaging was CAD403.21 ± CAD81.27,
mean cost of lab test was CAD44.72 ± CAD9.02, and mean 
cost of non-chemotherapy drugs was CAD44.51 ± CAD65.25.
Average cost of Chemotherapy drugs was CAD460.70 ±
CAD98.70. CONCLUSION: Advanced NSCLC patients on
chemotherapy use substantial health care resources in Canadian
setting. However, if not in end stage of life, patients have high
HRQoL and utility scores that warrant further investigation.
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OBJECTIVES: The aim of this study was to develop health state
descriptions for patients receiving chemotherapy for stable,
responding and progressive metastatic breast cancer (MBC).
Subsequent work will derive utility values for the health states
for use in cost utility analyses. METHODS: An interview dis-
cussion guide was produced based on literature review and clin-
ical input. This focused on the symptoms of MBC, impact on
different areas of functioning (physical, social, emotional, sexual,
and cognitive), health related quality of life (HRQL), severe hair
loss and ﬁve side effects of chemotherapy (all grade III–IV toxi-
cities). These included febrile neutropenia, hand-foot syndrome,
diarrhoea/vomiting, stomatitis, and fatigue. Health states were
developed and validated using cognitive debrieﬁng interviews
with oncologists and a focus group with oncology specialist
nurses. Fifteen health states (7 stable, 7 responding, 1 progres-
sive) described the symptoms, toxicities, HRQL and impact on
functioning. Health states combined stable, responding and pro-
gressive disease with grade III–IV side effects or hair loss. To sim-
plify the preference elicitation stage of this study the number of
health states were reduced by employing an orthogonal frac-
tional factorial design to combine disease stages with toxicities.
The contributory effect of each will be estimated using a regres-
sion model. RESULTS: Four main areas of functioning, physi-
cal, emotional, social and sexual, were identiﬁed as being
primarily affected in MBC. Patients responding to treatment
have the highest overall HRQL while those with progressive
disease have the lowest. The focus group discussion supported
the validity of the health states. CONCLUSION: Health states
describing the combined impact of MBC and grade III–IV toxi-
cities associated with chemotherapy treatment on patient’s
HRQL at different disease stages were developed. These health
states will be piloted and used in a societal based valuation study.
The ﬁnal health states will be presented.
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OBJECTIVES: In clinical trials, chemotherapy-related adverse
events (AEs) are classiﬁed according to the Common Toxicity
Criteria (CTC). This standardised method of reporting provides
clinicians with an overview of the level of medical intervention
required to treat AEs, but does not necessarily assess the impact
on a patient’s health-related quality of life (HRQL). We attempt
to translate CTC (version 2.0) ratings into a scale that reﬂects
the severity of various events on a patient’s HRQL. METHODS:
In this study, scores of impact on patient HRQL were assigned
to AEs experienced by advanced non-small cell lung cancer
(NSCLC) patients receiving second-line chemotherapy. This was
achieved through a pilot survey of a convenience sample of
